Американское общество гирудотерапии

Irritable Bowel Syndrome, Pain-Predominant (Investigational Adjunct)

Investigational adjunct for pain-predominant IBS refractory to dietary and pharmacologic therapy; low-FODMAP diet, antispasmodics, low-dose tricyclic antidepressants, and cognitive behavioral therapy or gut-directed hypnotherapy remain evidence-based.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?
Not FDA-cleared for irritable bowel syndrome, pain-predominant. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Какие доказательства существуют?
Tier C (investigational). No controlled trials. Evidence-based first-line management is dietary intervention (low-FODMAP diet has the strongest evidence), antispasmodics (hyoscyamine, peppermint oil), tricyclic antidepressants or SNRIs for pain, soluble fiber for constipation-predominant subtypes, eluxadoline or rifaximin for diarrhea-predominant or mixed subtypes, gut-directed hypnotherapy, and cognitive behavioral therapy.
Основные риски
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Bowel symptom flare around session days from stress and dietary disruption
  • Distraction from evidence-based dietary and pharmacologic interventions
Кому не следует это рассматривать
  • Patients with alarm features (rectal bleeding, weight loss, anemia, age over 50 without prior workup) — need GI workup first
  • Patients who have not tried low-FODMAP diet, antispasmodics, or appropriate medications
  • Patients with possible inflammatory bowel disease or celiac disease that has not been ruled out
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
О чём спросить врача
  • Have I had appropriate IBS workup excluding IBD, celiac, and other mimics?
  • Have I tried low-FODMAP diet under a dietitian's guidance?
  • Have I tried antispasmodics, peppermint oil, or a tricyclic antidepressant?
  • Have CBT or gut-directed hypnotherapy been considered?
  • What is the published evidence base for leeches in IBS?
  • How will success be measured?
Когда срочно обратиться за медицинской помощью
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Rectal bleeding, black or tarry stools, unintentional weight loss
  • Nighttime diarrhea waking from sleep
  • Severe abdominal pain not typical of IBS pattern

Что это НЕ означает

  • It does not mean leech therapy is FDA-cleared for IBS — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace low-FODMAP diet, antispasmodics, or psychological therapies.
  • It does not change the gut-brain axis dysregulation underlying IBS.
  • It does not exclude or treat IBD, celiac, or other mimics.
  • It does not have controlled-trial evidence in IBS.

Clinical Profile

Category
gastrointestinal
ICD-10
K58.0, K58.1, K58.2, K58.8, K58.9
Safety tier
medium

Evidence Summary

Irritable bowel syndrome (Rome IV) is recurrent abdominal pain associated with defecation or change in bowel habits, in the absence of structural disease. Pain-predominant phenotypes overlap with IBS-D, IBS-C, and IBS-M. Evidence-based management is dietary trial (low-FODMAP, with structured reintroduction), antispasmodics (hyoscine, peppermint oil), low-dose tricyclic antidepressants for pain, SSRIs for IBS-C with mood comorbidity, and gut-directed hypnotherapy or cognitive behavioral therapy with substantial RCT support. Linaclotide, plecanatide, and lubiprostone for IBS-C; eluxadoline, rifaximin, and alosetron for IBS-D. No published controlled trials of hirudotherapy exist for IBS. Abdominal placement in central European literature is anecdotal without efficacy data.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Alarm features (weight loss, GI bleeding, anemia, family history of GI cancer) — workup first
  • Inflammatory bowel disease
  • Active gastroenteritis or post-infectious IBS within 8 weeks
  • Stoma, ventral hernia, or abdominal wall pathology at placement site
  • Pregnancy or lactation

Related Conditions

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.

Irritable Bowel Syndrome, Pain-Predominant (Investigational Adjunct) — Hirudotherapy Evidence | ASH